Stock price when the opinion was issued
It produces medical devices which is a good business to be in. The aging population needs their products and there is a backlog from Covid. Their products change the quality of life and reduce hospital stays to a couple of days. 71% of its business comes from the U.S. and there is lots of growth internationally.
This is a great company, he says, with a well-established track record. The price is getting to the point, where you are paying a premium at this level. He would diversify into other holdings as well, ideally through an ETF such as IHI-N